We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Post-TAVR Pacemakers Linked to Higher Mortality Risk

By Daniel Beris
Posted on 22 Nov 2016
Permanent pacemaker (PPM) implantation soon after transcatheter aortic valve replacement (TAVR) often leads to worse outcomes, according to a new study.

Researchers at the Reading Health System (West Reading, PA, USA), Thomas Jefferson University (TJU; Philadelphia, PA, USA), and other institutions conducted a retrospective cohort study of 9,785 patients undergoing TAVR in the United States at 229 sites between November 2011 and September 2014. More...
Of these, 651 needed a permanent pacemaker within 30 days of the TAVR procedure. The researchers then used the data to evaluate the incidence, predictors, and clinical outcomes of PPM implantation following TAVR.

The results showed that PPM needs varied among those receiving self-expanding valves (25.1%) versus balloon-expanding valves (4.3%). Positive predictors of PPM implantation were age, prior conduction defect, and use of self-expanding valve. PPM implantation was also associated with longer median hospital stay, intensive care unit (ICU) stay, increased mortality, and a composite of mortality or heart failure admission at one year, but not with heart failure admission alone. The study was published in the November 2106 issue of JACC: Cardiovascular Interventions.

“While pacemakers can and do help save lives, what our study shows is that when they are placed within a month post-TAVR, they may be associated with worsened outcomes as compared to those who did not need pacemakers,” said lead author Opeyemi Fadahunsi, MBBS, MPH, of Reading Health System. “While TAVR is a great advance in medical care, cardiologists need to better understand both how to prevent patients from developing heart rhythm problems, and why patients who need pacemakers in the setting of recent TAVR have worsened outcomes.”

The percutaneous treatment of severe aortic valve disease using a TAVR prosthetic aortic valve replacement, without the need for open-heart surgery or cardiopulmonary bypass, is faster and less invasive than current open-heart procedures. TAVR has so far been proven effective in high-risk and inoperable patients, and could soon become the standard of care, even in moderate and low surgical risk patients.

Related Links:
Reading Health System
Thomas Jefferson University

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammo DR Retrofit Solution
DR Retrofit Mammography
Surgical Headlight
IsoTorch
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.